Innate and adaptive immune responses against coronavirus
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved..
Coronaviruses (CoVs) are a member of the Coronaviridae family with positive-sense single- stranded RNA. In recent years, the CoVs have become a global problem to public health. The immune responses (innate and adaptive immunity) are essential for elimination and clearance of CoVs infections, however, uncontrolled immune responses can result in aggravating acute lung injury and significant immunopathology. Gaining profound understanding about the interaction between CoVs and the innate and adaptive immune systems could be a critical step in the field of treatment. In this review, we present an update on the host innate and adaptive immune responses against SARS-CoV, MERS-CoV and newly appeared SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 132(2020) vom: 01. Dez., Seite 110859 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hosseini, Arezoo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive immune response |
|---|
| Anmerkungen: |
Date Completed 04.12.2020 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2020.110859 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316887803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316887803 | ||
| 003 | DE-627 | ||
| 005 | 20231225162045.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2020.110859 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM316887803 | ||
| 035 | |a (NLM)33120236 | ||
| 035 | |a (PII)S0753-3322(20)31051-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hosseini, Arezoo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Innate and adaptive immune responses against coronavirus |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2020 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Coronaviruses (CoVs) are a member of the Coronaviridae family with positive-sense single- stranded RNA. In recent years, the CoVs have become a global problem to public health. The immune responses (innate and adaptive immunity) are essential for elimination and clearance of CoVs infections, however, uncontrolled immune responses can result in aggravating acute lung injury and significant immunopathology. Gaining profound understanding about the interaction between CoVs and the innate and adaptive immune systems could be a critical step in the field of treatment. In this review, we present an update on the host innate and adaptive immune responses against SARS-CoV, MERS-CoV and newly appeared SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adaptive immune response | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Convalescent plasma therapy | |
| 650 | 4 | |a Innate immune response | |
| 650 | 4 | |a Monoclonal antibody therapy | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Hashemi, Vida |e verfasserin |4 aut | |
| 700 | 1 | |a Shomali, Navid |e verfasserin |4 aut | |
| 700 | 1 | |a Asghari, Faezeh |e verfasserin |4 aut | |
| 700 | 1 | |a Gharibi, Tohid |e verfasserin |4 aut | |
| 700 | 1 | |a Akbari, Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Gholizadeh, Saber |e verfasserin |4 aut | |
| 700 | 1 | |a Jafari, Abbas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 132(2020) vom: 01. Dez., Seite 110859 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2020 |g day:01 |g month:12 |g pages:110859 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2020.110859 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2020 |b 01 |c 12 |h 110859 | ||